Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 1 of 18 PageID #:
`16128
`
`
`
`
`
`
`
`EXHIBIT B
`
`
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 2 of 18 PageID #:
`16129
`
`Beazley, Jennalee
`From:
`Lauren M. Lesko <LLesko@rmmslegal.com>
`Sent:
`Wednesday, January 24, 2024 1:08 PM
`To:
`Gregory, Teagan; Mahaffy, Shaun; Bernal Anderson, Haylee; David Pogue; Douglass, Sean; Eylea
`Cc:
`Jamie O'Brien; Gordon Copland; Steve Ruby; M710 Team
`Subject:
`RE: Regeneron v. Mylan - Amgen intervention (Defs. Redactions)
`
`Follow Up Flag:
`Flag Status:
`
`Follow up
`Completed
`
`Teagan, thank you for confirming.
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5  
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M  
`
` 
` 
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Wednesday, January 24, 2024 11:52 AM 
`To: Lauren M. Lesko <LLesko@rmmslegal.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Lauren, 
` 
`Regeneron agrees that the proposed unsealing order can be submitted. 
` 
`Thanks, 
`Teagan 
` 
`Teagan James Gregory 
`
`1
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 3 of 18 PageID #:
`16130
`
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Lauren M. Lesko <LLesko@rmmslegal.com>  
`Sent: Tuesday, January 23, 2024 11:30 AM 
`To: Gregory, Teagan <TGregory@wc.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, we have not received any response to the below. Can you please let me know if we have Regeneron’s
`agreement to the proposed unsealing motion?
`
`Thanks,
`Lauren
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5  
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Lauren M. Lesko <LLesko@rmmslegal.com>  
`Sent: Friday, January 12, 2024 9:17 PM 
`To: 'Gregory, Teagan' <TGregory@wc.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan,
`
`We have made some minor edits to the joint motion and proposed order directing unsealing of various
`materials. An updated draft is provided for Regeneron’s review. We have implemented the following edits:
`
`2
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 4 of 18 PageID #:
`16131
`
`
`
` Per Regeneron’s request, we have removed Dkt. 188-18 and Dkt. 337-1 from the list of documents to be
`unsealed.
` Dkt. 469-5 must be filed in redacted format. We have removed it from the list of documents to be
`unsealed.
` Dkt. 494-5 and Dkt. 494-6 should not be unsealed. We have removed them from the list of documents
`to be unsealed.
` Dkt. 505 (and corresponding exhibits) are already on the public docket. We have removed them from
`the list of documents to be unsealed.
` Dkt. 593 is already on the public docket. We have removed it from the list of documents to be unsealed.
`
`
`We also note that on November 15, Regeneron indicated its intent to redact its own confidential information
`from Dkt. 505-5 and Dkt. 505-28. (See 11-15-23 H. Anderson email). Regeneron, however, has already
`authorized the unsealing of these documents and both are currently unredacted on the public docket. (See 9-29-
`23 D. Pogue email; Dkt. 639-1).
`
`Unless Regeneron has any further edits, we suggest the parties prepare to get this on file early next week. We
`will address the proposed redacted filings under separate cover.
`
`Best,
`Lauren
`
`
`L A U R E N M . L E S K O | P A R T N E R
`L L E S K O @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 7 2 4 5  
`M O B I L E | 6 3 0 . 2 0 5 . 2 3 9 0  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Friday, January 5, 2024 8:58 AM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Counsel, 
` 
`
`3
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 5 of 18 PageID #:
`16132
`Could you please advise as to the status of this? We would like to get these materials filed and also would like to update 
`Amgen’s counsel in the interim. If you respond to Amgen’s counsel, please copy us on that communication. 
` 
`Separately, I do not believe we have heard back from Defendants regarding proposed redactions to the Court’s 
`December 27 memorandum opinion. Please let us know if it would be helpful to discuss and when we can expect to 
`receive Defendants’ proposed redactions. I can be available to confer today. 
` 
`Thanks, 
`Teagan 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Tuesday, January 2, 2024 10:04 AM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Mahaffy, Shaun <SMahaffy@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Jeff, 
`
` I
`
` wanted to follow up on the below as well as my 12/28 email. Do Defendants have a status update on this 
`unsealing/redaction project? We were hoping to file at least the proposed unsealing order before the holidays, and 
`Amgen’s counsel inquired again about timing last Friday. 
` 
`Thanks, 
`Teagan  
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Friday, December 22, 2023 4:54 PM 
`To: Mahaffy, Shaun <SMahaffy@wc.com>; Gregory, Teagan <TGregory@wc.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: Re: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan and Shaun, 
`We're in receipt of Regeneron's feedback and are evaluating same. 
` 
`
`4
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 6 of 18 PageID #:
`16133
`
`Best, 
`Jeff 
` 
`
`J E F F A . M A R X | P A R T N E R
`J M A R X @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 6 3 0 8  
`O F F I C E | 3 1 2 . 5 2 7 . 2 1 5 7  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.
`
`From: Mahaffy, Shaun <SMahaffy@wc.com> 
`Sent: Friday, December 22, 2023 1:19:57 PM 
`To: Gregory, Teagan <TGregory@wc.com>; Jeff A. Marx <jmarx@rmmslegal.com>; Bernal Anderson, Haylee 
`<HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea 
`<Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions)  
` 
`Jeff, 
` 
`We have finished our review and the below issues concerning Regeneron confidential information were the only ones 
`we have identified at this point. Please send us corrected versions of the filings identified below for our final review. 
` 
`We would like to file at least the joint motion and proposed order directing unsealing of various materials today. Once 
`the two deletions we note below (188‐18 and 337‐1) have been made, we have no further edits. I note, however, that 
`Defendants’ Yesafili label—including the label’s description of the Yesafili drug formulation—again is included among 
`the documents to be unsealed in Defendants’ draft (469‐5). Defendants may wish to delete this if that was in error. If so, 
`please send us a redacted version for filing. 
` 
`Thanks, 
`Shaun 
` 
`Shaun P. Mahaffy 
`Williams & Connolly LLP 
`680 Maine Ave., S.W., Washington, DC 20024 
`(P) 202‐434‐5554 | (F) 202‐434‐5029 
`smahaffy@wc.com | www.wc.com 
` 
`
`5
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 7 of 18 PageID #:
`16134
`
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Thursday, December 21, 2023 11:28 PM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Jeff, 
` 
`We are finishing our review of these materials and expect to be done early tomorrow. In the meantime, we have the 
`following notes barring any last minute issues caught in our final review: 
` 
`
` Regeneron’s redacted filings  
`o The set you sent us on 12/13 appears to be correct, and we intend to file them as‐is. 
` Defendants’ redacted filings  
`o You have included 506 and 506‐2 in the folder you sent us. 506‐2 appears to be correct, but 506 includes 
`not only actual ECF 506, but also the associated exhibits including an only partially redacted version of 
`ECF 506‐2. Please fix and send back to us the versions of 506 and 506‐2 you intend to file. 
`o Similarly, you have included 508 and 508‐1 in the folder you sent us. 508, however, includes not only 
`ECF 508, but also its exhibits. Not all of our redactions from 508‐1 have been included in the larger 508 
`document. Please fix and send back to us the versions of 508 and 508‐1 you intend to file. 
`o We see that our additions/corrections to the redactions for 252, 252‐8, 252‐13, 252‐21, 252‐22, 360‐1, 
`360‐9, and 360‐10 have been implemented. Please confirm that other than those corrections and 
`making Mylan’s additional redactions to 187, 335, 335‐9, 360‐9, 591, 592, 602‐1, and 602‐2, as indicated 
`in your message below, Mylan has made no other changes to the set of proposed redacted filings it 
`previously provided on November 30 (i.e., Mylan has not made further redactions or removed any 
`redactions of either Mylan or RGN material). 
` Proposed Order  
`o Please remove from the proposed unsealing order 188‐18 and 337‐1. 
`
` 
`Thanks, 
`Teagan 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Wednesday, December 13, 2023 11:07 AM 
`To: Gregory, Teagan <TGregory@wc.com>; Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, 
`We’ve completed our further review of the pleadings requested by Amgen, and have the following
`notes and edits: 
`
`6
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 8 of 18 PageID #:
`16135
`
`Defendants’ pleadings 
`We have supplemented our prior set of redacted PDFs for Defendants’ pleadings and will send
`revised redacted PDFs shortly. In particular, we have supplemented redactions to Docket Nos.
`187, 335, 335-9, 360-9, 591, 592, 602-1, and 602-2.  
`Regeneron’s pleadings 
`We have supplemented our prior set of redacted PDFs for Regeneron’s pleadings and will send
`revised redacted PDFs shortly. In particular, we have supplemented redactions for Docket Nos.
`188, 299-1, 299-3, 299-35, 309, 313-1, 337, 337-2, 352-1, 497-13, 581, 597, 603-1, and 603-2. Please
`ensure these updated redacted PDFs are included in any version filed by Regeneron with the court. 
`Additionally, we note that Regeneron has applied redactions to Docket No. 391. It appears that
`Docket No. 391-1 is a duplicate of 391 and is currently unredacted, should Regeneron want to
`further review 391-1. 
` 
`We have further revised the draft proposed order to unseal various materials to accurately reflect
`the particular set of pleadings to be unsealed. For reference and Regeneron’s confirmation, a
`spreadsheet is attached noting the status of each pleading requested by Amgen in this round of
`review. Please let us know Regeneron’s feedback to the provided redacted PDFs and draft
`proposed order. I’m generally available to discuss.  
` 
`Jeff 
`
`J E F F A . M A R X | P A R T N E R  
`J M A R X @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 6 3 0 8  
`O F F I C E | 3 1 2 . 5 2 7 . 2 1 5 7  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4  
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.  
`From: Jeff A. Marx  
`Sent: Thursday, December 7, 2023 12:26 PM 
`To: Gregory, Teagan <TGregory@wc.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean 
`<SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, 
`
`7
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 9 of 18 PageID #:
`16136
`We’re still reviewing all of the pleadings requested by Amgen and the redacted PDFs to date. We
`expect to provide you with supplemental redacted PDFs by early next week, which will need to also
`be reflected on the joint motion to unseal (similar to your Dec. 4 email). I informed Amgen’s
`counsel (John Labbe) that our ongoing review will push into early next week, at which time we
`hope to file everything with the Court (pending Regeneron’s approval of the final PDFs as well).
`He was receptive and hopeful that the early-next week schedule will hold and they will see filings
`on the docket then. 
` 
`Jeff 
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Wednesday, December 6, 2023 1:32 PM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean 
`<SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Jeff, 
` 
`That’s my understanding as well. I would like to get the proposed order on file today if possible, even if we need another 
`day or two to work out any redaction implementation issues in the other documents. 
` 
`Teagan 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Wednesday, December 6, 2023 2:21 PM 
`To: Gregory, Teagan <TGregory@wc.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean 
`<SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, 
`We’ll provide you with a revised draft order as well as further revisions to redacted PDFs
`(pleadings for both Regeneron and Defendants) when our review is completed. Accordingly,
`Defendants are not filing anything with the Court until we and Regeneron are in agreement on the
`redacted PDFs and the proposed order. Can you please confirm likewise for Regeneron? 
` 
`Jeff 
`
`J E F F A . M A R X | P A R T N E R  
`J M A R X @ R M M S L E G A L . C O M  
`
`8
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 10 of 18 PageID #:
`16137
`
`D I R E C T | 3 1 2 . 2 2 2 . 6 3 0 8  
`O F F I C E | 3 1 2 . 5 2 7 . 2 1 5 7  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4  
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.  
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Wednesday, December 6, 2023 1:04 PM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean 
`<SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Thanks, Jeff. I’m available if you’d like to discuss anything. We would like to see the proposed order before it gets filed. 
` 
`Teagan 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Tuesday, December 5, 2023 4:33 PM 
`To: Gregory, Teagan <TGregory@wc.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue <drpogue@cdkrlaw.com>; Douglass, Sean 
`<SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, 
`Confirming we are in receipt of your email and the ZIP folders provided by Haylee. We are
`reviewing the PDFs and pleadings and will follow up after we complete our review process. 
` 
`
`J E F F A . M A R X | P A R T N E R  
`J M A R X @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 6 3 0 8  
`
`9
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 11 of 18 PageID #:
`16138
`
`O F F I C E | 3 1 2 . 5 2 7 . 2 1 5 7  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4  
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.  
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Monday, December 4, 2023 9:26 PM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland 
`<Gordon.Copland@Steptoe‐Johnson.com>; Steve Ruby <sruby@cdkrlaw.com>; M710 Team 
`<M710Team@rmmslegal.com> 
`Cc: Gregory, Teagan <TGregory@wc.com>; Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Jeff, 
` 
`Thanks for your email. I’ve attempted to address several issues from this redaction/unsealing process here, and I’m 
`happy to discuss tomorrow morning if you have any questions. 
` 
`First, I’ve provided responses to your questions below in red. 
` 
`Second, we have completed our review of Defendants’ proposed redacted filings and have the following notes and edits: 
` 
`
` 252 ‐ We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 252 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 252‐8 ‐ We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 252‐8 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 252‐13 ‐ We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 252‐13 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 252‐21 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 252‐21 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 252‐22 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 252‐22 – included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 360‐1 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 360‐1 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
`
`10
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 12 of 18 PageID #:
`16139
` 360‐9 – It appears Defendants missed a few of our requested redactions in this document. We also would like to 
`supplement our prior set of redactions, and we will send a new version. Please ensure the redactions in the 
`version of 360‐9 included in the FTP to follow are implemented in any version filed by Defendants. 
` 360‐10 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 360‐10 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 506‐2 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 506‐2 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
` 508‐1 – We would like to supplement our prior set of redactions and will send a new version. Please ensure the 
`redactions in the version of 508‐1 included in the FTP to follow are implemented in any version filed by 
`Defendants. 
`
` 
`Third, as noted in my email Saturday morning, we’ve further reviewed the draft proposed order to unseal various 
`materials. We have identified instances in which the filings Mylan lists for unsealing were or should have been the 
`subject of redaction requests from Regeneron. Please remove the following documents from the proposed order and 
`instead file redacted versions: 252, 252‐8, 252‐13, 252‐21, 252‐22. Pdfs of Regeneron’s redactions will follow by 
`separate FTP.  
` 
`Fourth, as noted below, we’ll also be sending by FTP an updated set of Regeneron filings we intend to file in redacted 
`form. This set adds the Regeneron post‐trial materials you flag below to the collection we sent you Saturday morning. It 
`also addresses your below request as to 469 and 491. 
` 
`Thanks, 
`Teagan 
` 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Monday, December 4, 2023 12:24 PM 
`To: Gregory, Teagan <TGregory@wc.com>; Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Teagan, 
`We have reviewed Regeneron’s redacted pleadings and redline draft Motion to Unseal provided to
`us this weekend and have the below follow-up: 
` Defendants provided redactions to DI 299-33. We believe that Regeneron intends to leave
`this filing under seal since we did not receive a redacted PDF for DI 299-33 from you and
`the pleading is not included on the draft motion to unseal. Can you please confirm. That is
`correct. We intend to keep 299-33 under seal. 
` Defendants provided redactions to exhibits DI 469-2 and DI 491-1. Regeneron provided us
`with single PDFs for each of DI 469 and DI 491 and the associated exhibits. We believe the
`
`11
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 13 of 18 PageID #:
`16140
`exhibits at DI 469-2 and 491-1 should be individually filed in redacted form with the Court
`and the remaining pleadings associated with DI 469 and DI 491 should be unsealed and
`included in the draft motion (i.e., unseal DI 469, 469-1, 469-3, 469-4, 469-5, 469-6; unseal
`DI 491, 491-2, 491-3, 491-4, 491-5). We’re not sure that’s necessary, but we’re happy to do
`so. 
` We (Defendants and Regeneron) previously provided to Amgen and Celltrion, via email,
`post-trial briefing and closing argument demonstratives. Amgen and Celltrion requested
`these be filed on the docket. Can you confirm that Regeneron is filing with the Court
`redacted PDFs for DI 581, 589, 590, 597, and 603-1, and that DI 603-2 should be unsealed.
`If so, please provide us with redacted PDFs for our final review. Relatedly, Defendants
`provided Regeneron with redacted PDFs for DI 591, 592, and 602-1, and have included DI
`602-2 in the daft motion for unsealing. If Defendants wish to file redacted versions
`of/unseal these materials now, we do not object. We would just plan to file the redacted
`versions of 581, 589, 590, 597, and 603-1 that you previously sent to Amgen’s and Celltrion’s
`counsel on October 12, but we’ll send them back to you today in our FTP of proposed
`redacted Regeneron filings so you can confirm there are no issues. As for 603-2, we sent
`your team a letter earlier today noting that it contains information Defendants have
`sometimes treated as confidential. Please let us know how you’d like us to proceed with
`respect to that slide deck. 
`
` 
`I’m available this afternoon between noon and 3pm CST to discuss if you would like. We look
`forward to receiving Regeneron’s feedback to Defendants’ redacted pleadings. 
`
`J E F F A . M A R X | P A R T N E R  
`J M A R X @ R M M S L E G A L . C O M  
`D I R E C T | 3 1 2 . 2 2 2 . 6 3 0 8  
`O F F I C E | 3 1 2 . 5 2 7 . 2 1 5 7  
`
`S I X W E S T H U B B A R D S T R E E T | C H I C A G O I L 6 0 6 5 4  
`W W W . R M M S L E G A L . C O M  
`
` 
`
`This email message and any attachments are being sent by Rakoczy Molino Mazzochi
`Siwik LLP, are confidential, and may be privileged. If you are not the intended recipient,
`please notify us immediately by replying to this message, and destroy all copies of this
`message and any attachments. Thank you.  
`From: Gregory, Teagan <TGregory@wc.com>  
`Sent: Saturday, December 2, 2023 10:13 AM 
`To: Jeff A. Marx <jmarx@rmmslegal.com>; Bernal Anderson, Haylee <HAnderson@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`
`12
`
`

`

`Case 1:23-cv-00089-TSK-JPM Document 128-2 Filed 03/06/24 Page 14 of 18 PageID #:
`16141
`
`Jeff, 
` 
`As discussed, please find attached our draft additions to the proposed order. We are performing some additional checks 
`this weekend and will confirm with you on Monday whether we have any further edits to the proposed order. 
`
` I
`
` am also sending you by separate FTP the set of Regeneron pleadings with redactions we tentatively plan to file next 
`week, again subject to our further review and Defendants’ review. 
` 
`Thanks, 
`Teagan 
` 
`Teagan James Gregory 
`Williams & Connolly LLP 
`680 Maine Avenue SW, Washington, DC 20024 
`(P) 202‐434‐5178 | (F) 202‐434‐5029 
`tgregory@wc.com | www.wc.com/tgregory 
` 
`From: Jeff A. Marx <jmarx@rmmslegal.com>  
`Sent: Monday, November 27, 2023 3:44 PM 
`To: Bernal Anderson, Haylee <HAnderson@wc.com>; Gregory, Teagan <TGregory@wc.com>; David Pogue 
`<drpogue@cdkrlaw.com>; Douglass, Sean <SDouglass@wc.com>; Eylea <Eylea@wc.com> 
`Cc: Jamie O'Brien <Jamie.Obrien@Steptoe‐Johnson.com>; Gordon Copland <Gordon.Copland@Steptoe‐Johnson.com>; 
`Steve Ruby <sruby@cdkrlaw.com>; M710 Team <M710Team@rmmslegal.com> 
`Subject: RE: Regeneron v. Mylan ‐ Amgen intervention (Defs. Redactions) 
` 
`Haylee and Teagan, 
`We’ve completed our review of Defendants’ pleadings. An updated spreadsheet is attached for
`reference and your records. We’ll complete redactions of the PDFs and file with the Court this
`week. Relatedly, a draft joint motion to unseal is attached based on our prior joint filing at DI 639.
`We have added Defendants’ pleadings that were originally filed under seal and no confidential
`information has been identified in this review round. Please add Regeneron’s pleadings where
`appropriate. 
` 
`I’m generally available to discuss tomorrow if you’d prefer. 
` 
`Jeff 
`
`J E F F A . M A R X